Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human immunodeficiency virus 1

ABSTRACT: Full-length HIV-1 envelope sequences

PROVIDER: PRJNA320111 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3539910_subreads.fastq.gz	Fastqsanger.gz
	SRR3539911_subreads.fastq.gz	Fastqsanger.gz
	SRR3539912_subreads.fastq.gz	Fastqsanger.gz
	SRR3539913_subreads.fastq.gz	Fastqsanger.gz
	SRR3539916_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Human immunodeficiency virus 1

Project description:Full-length sequencing of a heterogeneous five HIV-1 virus mixture

| PRJNA217811 | ENA

Human immunodeficiency virus 1

Project description:HIV-PULSE: A long-read sequencing assay for high-throughput near full-length HIV-1 proviral genome characterization

| PRJNA925880 | ENA

Human immunodeficiency virus 1

Project description:HIV-1 Envelope Clinical Isolates from Vicriviroc Resistant Subjects

| PRJNA317236 | ENA

Human immunodeficiency virus 1

Project description:Human immunodeficiency virus 1 near full length genome sequencing by NGS

| PRJNA419915 | ENA

Innate protection against intrarectal SIV acquisition by a live Simian-Human immunodeficiency virus vaccine

Project description:Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical against SIV/HIV acquisition. Here, we evaluated the efficacy of a SHIV vaccine against SIVmac251 challenge, where the role of antibody was excluded as there was no cross-reactivity between SIV and SHIV Envelope antibodies. After eight low-dose rectal challenges with SIVmac251, 12 SHIV-vaccinated animals demonstrated 83% efficacy, compared to six naïve controls, suggesting protection could be achieved in the absence of anti-Envelope antibodies. Interestingly, CD8+ T cells (and some NK cells) were not essential for the preventing viral acquisition, as none of the CD8-depleted macaques were infected by SIVmac251 challenges. Initial investigation of protective innate immunity revealed that protected animals had elevated pathways related to platelet aggregation/activation, and reduced pathways related to interferon and responses to virus. Moreover, higher expression of platelet factor 4 (PF4) on circulating platelet-leukocyte aggregates was associated with reduced viral acquisition. Our data highlighted the importance of innate immunity and may provide new opportunities for novel HIV vaccines or therapeutic strategy development.

2024-09-30 | GSE242726 | GEO

Human immunodeficiency virus 1

Project description:Guiding the humoral response against HIV-1 toward a MPER proximal region by immunization with a VLP-formulated antibody-selected envelope variant

| PRJNA495005 | ENA

Human immunodeficiency virus

Project description:Comparison of HIV-1 and HIV-2 Mutagenesis by Illumina Sequencing

| PRJNA287455 | ENA

Schlafen 5 Suppresses Human Immunodeficiency Virus Type 1 Transcription by Commandeering Cellular Epigenetic Machinery

Project description:Schlafen-5 (SLFN5) is an interferon-induced protein of the Schlafen family which are involved in immune responses and oncogenesis. To date, little is known regarding its anti-HIV-1 function. Here, the authors report that overexpression of SLFN5 inhibits HIV-1 replication and reduces viral mRNA levels, whereas depletion of endogenous SLFN5 promotes HIV-1 replication. Moreover, they show that SLFN5 markedly decreases the transcriptional activity of HIV-1 long terminal repeat (LTR) via binding to two sequences in the U5-R region, which consequently represses the recruitment of RNA polymerase Ⅱ to the transcription initiation site. Mutagenesis studies show the importance of nuclear localization and the N-terminal 1-570 amino acids fragment in the inhibition of HIV-1. Further mechanistic studies demonstrate that SLFN5 interacts with components of the PRC2 complex, G9a and Histone H3, thereby promoting H3K27me2 and H3K27me3 modification leading to silencing HIV-1 transcription. In concert with this, they find that SLFN5 blocks the activation of latent HIV-1. Altogether, their findings demonstrate that SLFN5 is a transcriptional repressor of HIV-1 through epigenetic modulation and a potential determinant of HIV-1 latency.

2022-05-24 | GSE197700 | GEO

Variability in the Glycosylation Patterns of gp120 Proteins from Different Human Immunodeficiency Virus Type 1 Isolates Expressed in Different Host Cells

Project description:The mature HIV-1 envelope (Env) glycoprotein is composed of gp120, the exterior subunit, and gp41, the transmembrane subunit assembled as trimer by noncovalent interaction. There is a great body of literature to prove that gp120 binds to CD4 first, then to the co-receptor. We have recently demonstrated that gp120 cannot bind to the co-receptor without first interacting with CD4. Previous studies provided different glycomic maps for the HIV-1 gp120. Here, we build on previous work to report that the use of LC-MS/MS, in conjunction with hydrophilic interaction liquid chromatography (HILIC) enrichment to glycosylation sites, is associated with the assorted neutralizing or binding events of glycosylation targeted antibodies from different clades or strains. In this study, the microheterogeneity of the glycosylation from 4 different clades of gp120s is deeply investigated. Aberrant glycosylation patterns were detected on gp120 originated from different clades, viral sequences and host cells. The results of this study may help provide better understanding of the mechanism of how the glycans participate in antibody neutralizing process that target glycosylation sites.

2021-11-01 | PXD027353 | Pride

Human immunodeficiency virus 1

Project description:HIV-1 genome sequencing, genetic analysis of HIV-1 recombinant forms

| PRJDB13369 | ENA